- Home
- WHF vs ELDN Comparison
WHF vs ELDN Comparison
Compare WHF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- ELDN
- Stock Information
- Founded
- WHF 2011
- ELDN 2004
- Country
- WHF United States
- ELDN United States
- Employees
- WHF N/A
- ELDN N/A
- Industry
- WHF Finance Companies
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- ELDN Health Care
- Exchange
- WHF Nasdaq
- ELDN Nasdaq
- Market Cap
- WHF 212.0M
- ELDN 178.4M
- IPO Year
- WHF 2012
- ELDN N/A
- Fundamental
- Price
- WHF $8.73
- ELDN $2.72
- Analyst Decision
- WHF Sell
- ELDN Strong Buy
- Analyst Count
- WHF 4
- ELDN 2
- Target Price
- WHF $10.83
- ELDN $12.50
- AVG Volume (30 Days)
- WHF 96.6K
- ELDN 198.6K
- Earning Date
- WHF 08-07-2025
- ELDN 08-18-2025
- Dividend Yield
- WHF 17.66%
- ELDN N/A
- EPS Growth
- WHF N/A
- ELDN N/A
- EPS
- WHF 0.39
- ELDN N/A
- Revenue
- WHF $86,143,000.00
- ELDN N/A
- Revenue This Year
- WHF N/A
- ELDN N/A
- Revenue Next Year
- WHF N/A
- ELDN N/A
- P/E Ratio
- WHF $22.16
- ELDN N/A
- Revenue Growth
- WHF N/A
- ELDN N/A
- 52 Week Low
- WHF $8.44
- ELDN $2.30
- 52 Week High
- WHF $12.73
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- WHF 38.47
- ELDN 35.43
- Support Level
- WHF $9.18
- ELDN $2.76
- Resistance Level
- WHF $9.66
- ELDN $2.90
- Average True Range (ATR)
- WHF 0.16
- ELDN 0.16
- MACD
- WHF -0.00
- ELDN -0.03
- Stochastic Oscillator
- WHF 0.00
- ELDN 4.39
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.